申请人:MitoPower, LLC
公开号:US20200397807A1
公开(公告)日:2020-12-24
The disclosure provides nicotinamide riboside (NR), the reduced form of NR (NRH), nicotinic acid riboside (NAR), the reduced form of NAR (NARH), derivatives thereof, compositions thereof and uses thereof. The NR and NAR derivatives have improved stability and bioavailability compared to NR and NAR. NR, NRH, NAR, NARH, and derivatives thereof can increase cellular NAD
+
levels and enhance mitochondrial and cellular function and cell viability. Therefore, NR, NRH, NAR, NARH, and derivatives thereof, whether alone or in combination with one or more additional therapeutic agents (e.g., a mitochondrial uncoupler or/and a PARP inhibitor), are useful for treating mitochondrial diseases, mitochondria-related diseases and conditions, metabolic disorders, and other disorders and conditions.
该披露提供烟酰胺核糖苷(NR)、烟酰胺核糖苷的还原形式(NRH)、烟酸核糖苷(NAR)、烟酸核糖苷的还原形式(NARH)、以及它们的衍生物、组合物和用途。与NR和NAR相比,NR和NAR的衍生物具有更好的稳定性和生物利用度。NR、NRH、NAR、NARH和它们的衍生物可以增加细胞NAD+水平,增强线粒体和细胞功能以及细胞存活能力。因此,NR、NRH、NAR、NARH和它们的衍生物,无论是单独使用还是与一个或多个额外治疗剂(例如线粒体解耦蛋白抑制剂和/或PARP抑制剂)结合使用,都可用于治疗线粒体疾病、与线粒体相关的疾病和症状、代谢紊乱以及其他疾病和症状。